Anti-Rheumatic Drugs - France

France

The Anti-Rheumatic Drugs market in France is expected to achieve a revenue of €0.63bn by the year 2024.
Furthermore, it is projected to exhibit an annual growth rate (CAGR 2024-2029) of 0.00%, leading to a market volume of €0.63bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue, with an estimated €31,850.00m in the year 2024.
France is experiencing a growing demand for innovative anti-rheumatic drugs, driven by its aging population and increasing prevalence of rheumatoid arthritis.

Key regions: Germany, United States, India, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The market for Anti-Rheumatic Drugs in France has been showing a steady growth over the past few years.

Customer preferences: Patients in France prefer Anti-Rheumatic Drugs that are effective in treating the disease and have minimal side effects. They also tend to prefer drugs that are easy to administer and have a shorter duration of treatment.

Trends in the market: The trend in the Anti-Rheumatic Drugs market in France is towards the use of biologics, which are more effective than traditional disease-modifying anti-rheumatic drugs (DMARDs) and have fewer side effects. The market is also seeing an increase in the use of biosimilars, which are cheaper versions of biologics. Additionally, there is a growing trend towards the use of combination therapies to treat rheumatoid arthritis, which is the most common form of rheumatic disease in France.

Local special circumstances: France has a universal healthcare system, which means that healthcare is accessible to all citizens regardless of their financial status. This has resulted in a high demand for Anti-Rheumatic Drugs in the country. Additionally, France has a large aging population, which is more prone to rheumatic diseases. This has further contributed to the growth of the Anti-Rheumatic Drugs market in the country.

Underlying macroeconomic factors: The French economy has been growing steadily over the past few years, which has led to an increase in healthcare spending. This has resulted in more funding being allocated towards the treatment of rheumatic diseases. Additionally, the French government has implemented policies to encourage the use of biosimilars, which has led to an increase in their adoption in the market. The government has also been working towards reducing the cost of healthcare, which has led to an increase in the use of combination therapies.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.